Signals
A second oral pill for weight loss changes the access barrier.
It does not change the biology.
What Foundayo Is
Foundayo (orforglipron), FDA approved April 1, is the first oral GLP-1 with:
- No fasting requirement
- No water restriction
- No empty stomach protocol
Once daily. $149/month self-pay. Shipping April 6.
More patients will start. That is genuinely good news.
Here is what I want us to keep in mind alongside the headlines.
What a Pill Does Not Change
The Lean Mass Signal
25–40% of weight lost on GLP-1s can come from lean mass without countermeasures. An oral formulation does not change that.
Protein targets, resistance training, and monitoring still matter on day one — arguably more now, because more patients will be starting without the clinical preparation that often accompanies an injectable conversation.
The Discontinuation Reality
Only about 14% of patients remain on GLP-1 therapy at three years without structured support. When they stop, the biology does exactly what biology does. The weight regain is not muscle.
An oral formulation lowers the barrier to starting.
It does not lower the barrier to stopping.
What Still Has to Be True
The ecosystem still has to outlast the medication.
Foundayo opens a door for patients who never would have walked through it. Our job — clinicians, employers, organizations — is to make sure something meaningful is waiting on the other side.
What are you already hearing from patients and colleagues?